{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated-interferon+alfa-2a&page=3", "query": { "intervention": "Pegylated-interferon alfa-2a", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 199, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated-interferon+alfa-2a&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated-interferon+alfa-2a&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T19:33:17.553Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00720434", "title": "A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "PF-00868554", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2008-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2013-08-26", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 9, "location_summary": "La Jolla, California • San Francisco, California • Orlando, Florida + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720434" }, { "nct_id": "NCT01482390", "title": "A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Mericitabine", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-11-30", "completion_date": "2014-01-31", "has_results": false, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482390" }, { "nct_id": "NCT00483938", "title": "The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Pegylated-interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 236, "start_date": "2007-06", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-01-23", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00483938" }, { "nct_id": "NCT01001754", "title": "Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "PEG-rIL-29", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ZymoGenetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 600, "start_date": "2010-05", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2011-12-05", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 29, "location_summary": "Beverly Hills, California • Coronado, California • La Jolla, California + 26 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001754" }, { "nct_id": "NCT00077636", "title": "ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1469, "start_date": "2003-12", "completion_date": "2006-03", "has_results": true, "last_update_posted_date": "2016-02-23", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077636" }, { "nct_id": "NCT01057667", "title": "A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" }, { "name": "Ribavirin [Copegus]", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 168, "start_date": "2010-02", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 19, "location_summary": "La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01057667" }, { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" }, { "nct_id": "NCT00962975", "title": "A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2009-09", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-04-08", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00962975" }, { "nct_id": "NCT05005507", "title": "A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "PegIFN-alpha-2a", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "TAF", "type": "DRUG" }, { "name": "ETV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2021-11-03", "completion_date": "2021-12-29", "has_results": true, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 1, "location_summary": "Hillsborough, New Jersey", "locations": [ { "city": "Hillsborough", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005507" }, { "nct_id": "NCT00394277", "title": "A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1175, "start_date": "2007-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-10-05T19:33:17.553Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00394277" } ] }